{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:07:34Z","timestamp":1787238454353,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Painful diabetic peripheral neuropathy (PDPN) is a key concern in clinical practice. In this systematic review and meta-analysis, we compared duloxetine and placebo treatments in terms of their efficacy and safety in patients with PDPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following the PRISMA guidelines, we searched the Cochrane Library, PubMed, and Embase databases for relevant English articles published before January 11, 2021. Treatment efficacy and safety were assessed in terms of pain improvement, patient-reported health-related performance, and patients\u2019 quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We reviewed a total of 7 randomized controlled trials. Regarding pain improvement, duloxetine was more efficacious than placebo (mean difference [MD]\u2009\u2212\u20090.89; 95% confidence interval [CI]\u2009\u2212\u20091.09 to\u2009\u2212\u20090.69;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.00001). Furthermore, duloxetine significantly improved the patients\u2019 quality of life, which was assessed using the Clinical Global Impression severity subscale (MD\u2009\u2212\u20090.48; 95% CI\u2009\u2212\u20090.61 to\u2009\u2212\u20090.36;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.00001), Patient Global Impression of Improvement scale (MD\u2009\u2212\u20090.50; 95% CI\u2009\u2212\u20090.64 to\u2009\u2212\u20090.37;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.00001), and European Quality of Life Instrument 5D version (MD 0.04; 95% CI 0.02 to 0.07;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.0002). Severe adverse events were rare, whereas nausea, somnolence, dizziness, fatigue, constipation, and decreased appetite were common; approximately, 12.6% of all patients dropped out because of the common symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Duloxetine is more efficacious than placebo treatments in patients with PDPN. The rarity of severe adverse events indicates that duloxetine is safe. When a 60-mg dose is insufficient, 120\u00a0mg of duloxetine may improve PDPN symptoms. Our findings may help devise optimal treatment strategies for PDPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42021225451<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-023-02185-6","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:03:09Z","timestamp":1679403789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"12","author":[{"given":"Chung-Sheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Chun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4884","authenticated-orcid":false,"given":"Che-Hsiung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"2185_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00002508-200211000-00001","volume":"18","author":"RH Dworkin","year":"2002","unstructured":"Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain. 2002;18:343\u20139.","journal-title":"Clin J Pain"},{"key":"2185_CR2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","volume":"27","author":"AJ Boulton","year":"2004","unstructured":"Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458\u201386.","journal-title":"Diabetes Care"},{"key":"2185_CR3","first-page":"16","volume":"58","author":"AN Poncelet","year":"2003","unstructured":"Poncelet AN. Diabetic polyneuropathy. Risk factors, patterns of presentation, diagnosis, and treatment. Geriatrics. 2003;58:16\u20138, 24-15, 30.","journal-title":"Geriatrics"},{"key":"2185_CR4","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2337\/dc12-1964","volume":"36","author":"S Tesfaye","year":"2013","unstructured":"Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36:2456\u201365.","journal-title":"Diabetes Care"},{"key":"2185_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00002508-200309000-00004","volume":"19","author":"SJ Krause","year":"2003","unstructured":"Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306\u201314.","journal-title":"Clin J Pain"},{"key":"2185_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0168-8227(99)00112-6","volume":"47","author":"BS Galer","year":"2000","unstructured":"Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"2185_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1017\/S0140525X97251484","volume":"20","author":"TJ Coderre","year":"1997","unstructured":"Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci. 1997;20:404\u201319; discussion 435-513.","journal-title":"Behav Brain Sci"},{"key":"2185_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.diabres.2014.01.002","volume":"104","author":"H Zuo","year":"2014","unstructured":"Zuo H, Shi Z, Hussain A. Prevalence, trends and risk factors for the diabetes epidemic in China: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014;104:63\u201372.","journal-title":"Diabetes Res Clin Pract"},{"key":"2185_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0006-8993(93)90210-E","volume":"616","author":"FM Clark","year":"1993","unstructured":"Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res. 1993;616:200\u201310.","journal-title":"Brain Res"},{"key":"2185_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev.ne.07.030184.001521","volume":"7","author":"AI Basbaum","year":"1984","unstructured":"Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309\u201338.","journal-title":"Annu Rev Neurosci"},{"key":"2185_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-0348-8183-8_5","volume":"58","author":"DT Wong","year":"2002","unstructured":"Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res. 2002;58:169\u2013222.","journal-title":"Prog Drug Res"},{"key":"2185_CR12","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/ijms18112483","volume":"18","author":"H Obata","year":"2017","unstructured":"Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18:2483.","journal-title":"Int J Mol Sci"},{"key":"2185_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40122-017-0087-0","volume":"6","author":"G Cruccu","year":"2017","unstructured":"Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6:35\u201342.","journal-title":"Pain Ther"},{"key":"2185_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","volume":"152","author":"M Haanp\u00e4\u00e4","year":"2011","unstructured":"Haanp\u00e4\u00e4 M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14\u201327.","journal-title":"Pain"},{"key":"2185_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e1188.","journal-title":"Eur J Neurol"},{"key":"2185_CR16","volume-title":"National institute for health and care excellence: clinical guidelines, in neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings","author":"Centre for Clinical Practice at N","year":"2013","unstructured":"Centre for Clinical Practice at N. National institute for health and care excellence: clinical guidelines, in neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Care Excellence, (UK) Copyright \u00a9 2013, National Institute for Health and Care Excellence; 2013."},{"key":"2185_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","volume":"19","author":"D Moulin","year":"2014","unstructured":"Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328\u201335.","journal-title":"Pain Res Manag"},{"key":"2185_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","volume":"98","author":"R Price","year":"2022","unstructured":"Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Neurology. 2022;98:31.","journal-title":"Neurology"},{"key":"2185_CR19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"V Bril","year":"2011","unstructured":"Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758\u201365.","journal-title":"Neurology"},{"key":"2185_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4065\/mcp.2010.0681","volume":"86","author":"RJ Tanenberg","year":"2011","unstructured":"Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86:615\u201326.","journal-title":"Mayo Clin Proc"},{"key":"2185_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40:136.","journal-title":"Diabetes Care"},{"key":"2185_CR22","doi-asserted-by":"publisher","unstructured":"Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1):CD007115. https:\/\/doi.org\/10.1002\/14651858.CD007115.pub3.","DOI":"10.1002\/14651858.CD007115.pub3"},{"key":"2185_CR23","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:e123-130.","journal-title":"Open Med"},{"key":"2185_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain"},{"key":"2185_CR25","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23:129\u201338.","journal-title":"Ann Acad Med Singap"},{"key":"2185_CR26","volume-title":"SF-36 Health survey manual and interpretation guide","author":"JE Ware","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M. SF-36 Health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993."},{"key":"2185_CR27","volume-title":"ECDEU assessment manual for psychopharmacology, revised, 1976","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised, 1976. Rockville, MD US Department of Health: Education, and Welfare; 1976."},{"key":"2185_CR28","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont (Pa\u202f: Township)). 2007;4:28\u201337.","journal-title":"Psychiatry (Edgmont (Pa. : Township))"},{"key":"2185_CR29","volume-title":"EuroQoL instrument: an index of health-related quality of life. In: Quality of life and pharmacoeconomics in clinical trials","author":"P Kind","year":"1996","unstructured":"Kind P. EuroQoL instrument: an index of health-related quality of life. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Lippincott\u2013Raven: Philadelphia; 1996.","edition":"2"},{"key":"2185_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"R Melzack","year":"1987","unstructured":"Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191\u20137.","journal-title":"Pain"},{"key":"2185_CR31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2185_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"2185_CR33","volume-title":"Review Manager (RevMan) [Computer program] Version 5.4","author":"TC Collaboration","year":"2020","unstructured":"Collaboration TC. Review Manager (RevMan) [Computer program] Version 5.4. 2020."},{"key":"2185_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.2040-1124.2010.00073.x","volume":"2","author":"H Yasuda","year":"2011","unstructured":"Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Investig. 2011;2:132\u20139.","journal-title":"J Diabetes Investig"},{"key":"2185_CR35","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D\u2019Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411\u201320.","journal-title":"Neurology"},{"key":"2185_CR36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346\u201356.","journal-title":"Pain Med"},{"key":"2185_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109\u201318.","journal-title":"Pain"},{"key":"2185_CR38","first-page":"3184","volume":"123","author":"Y Gao","year":"2010","unstructured":"Gao Y, Ning G, Jia WP, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010;123:3184\u201392.","journal-title":"Chin Med J (Engl)"},{"key":"2185_CR39","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.pain.2012.01.009","volume":"153","author":"MC Rowbotham","year":"2012","unstructured":"Rowbotham MC, Arslanian A, Nothaft W, et al. Efficacy and safety of the \u03b14\u03b22 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain. 2012;153:862\u20138.","journal-title":"Pain"},{"key":"2185_CR40","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/ijcp.12641","volume":"69","author":"Y Gao","year":"2015","unstructured":"Gao Y, Guo X, Han P, et al. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo. Int J Clin Pract. 2015;69:957\u201366.","journal-title":"Int J Clin Pract"},{"key":"2185_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.curtheres.2006.10.001","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Raskin J, Rosen A, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: an open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp. 2006;67:283\u2013304.","journal-title":"Curr Ther Res Clin Exp"},{"key":"2185_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1526-4637.2006.00258.x","volume":"8","author":"JF Wernicke","year":"2007","unstructured":"Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503\u201313.","journal-title":"Pain Med"},{"key":"2185_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jdi.12361","volume":"7","author":"H Yasuda","year":"2016","unstructured":"Yasuda H, Hotta N, Kasuga M, et al. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study. J Diabetes Investig. 2016;7:100\u20138.","journal-title":"J Diabetes Investig"},{"key":"2185_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/jpm.2006.9.29","volume":"9","author":"J Raskin","year":"2006","unstructured":"Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29\u201340.","journal-title":"J Palliat Med"},{"key":"2185_CR45","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fendo.2019.00929","volume":"10","author":"H Yang","year":"2019","unstructured":"Yang H, Sloan G, Ye Y, et al. New perspective in diabetic neuropathy: from the periphery to the brain, a call for early detection, and precision medicine. Front Endocrinol (Lausanne). 2019;10:929.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2185_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0253-7613.91867","volume":"44","author":"P Devi","year":"2012","unstructured":"Devi P, Madhu K, Ganapathy B, et al. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012;44:51\u20136.","journal-title":"Indian J Pharmacol"},{"key":"2185_CR47","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2337\/dc12-0656","volume":"35","author":"J Boyle","year":"2012","unstructured":"Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35:2451\u20138.","journal-title":"Diabetes Care"},{"key":"2185_CR48","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","volume":"154","author":"S Tesfaye","year":"2013","unstructured":"Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2013a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616\u201325.","journal-title":"Pain"},{"key":"2185_CR49","first-page":"e5293","volume":"11","author":"W Shahid","year":"2019","unstructured":"Shahid W, Kumar R, Shaikh A, et al. Comparison of the efficacy of duloxetine and pregabalin in pain relief associated with diabetic neuropathy. Cureus. 2019;11:e5293.","journal-title":"Cureus"},{"key":"2185_CR50","doi-asserted-by":"publisher","first-page":"639","DOI":"10.7326\/M14-0511","volume":"161","author":"ML Griebeler","year":"2014","unstructured":"Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161:639\u201349.","journal-title":"Ann Intern Med"},{"key":"2185_CR51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.clinthera.2017.02.010","volume":"39","author":"F van Nooten","year":"2017","unstructured":"van Nooten F, Treur M, Pantiri K, et al. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39:787-803.e718.","journal-title":"Clin Ther"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-023-02185-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:05:43Z","timestamp":1679403943000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-023-02185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2185"],"URL":"https:\/\/doi.org\/10.1186\/s13643-023-02185-6","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}